[ad_1]
Altimmune, Inc. (ALT) Jefferies London Healthcare Convention 2025 November 20, 2025 3:00 AM EST
Firm Contributors
Vipin Garg – President, CEO & Director
Christophe Arbet-Engels – Chief Medical Officer
Convention Name Contributors
Jiale Track – Jefferies LLC, Analysis Division
Presentation
Jiale Track
Jefferies LLC, Analysis Division
All proper. Good morning, everybody, to Jefferies’ London Healthcare Convention 2025. My identify is Roger Track, one of many senior analyst protecting SMID-cap biotech within the U.S. It’s my nice pleasure to have the subsequent hearth chat with Altimmune. We’ve Vipin and Christophe. Good to satisfy you right here.
Vipin Garg
President, CEO & Director
Thanks for having us right here.
Query-and-Reply Session
Jiale Track
Jefferies LLC, Analysis Division
Completely. All proper. So perhaps, Vipin, you can begin with some elevated pitch after which to see what is the state of the union for Altimmune immediately?
Vipin Garg
President, CEO & Director
Sure. So we’re growing — as you recognize, we’re growing a glucagon GLP-1 twin receptor agonist for MASH, for liver ailments, MASH, AUD and ALD, it is a rationally designed molecule with 1:1 ratio of GLP-1 and glucagon. And we predict that is essential actually in an effort to drive the glucagon perform, glucagon works immediately within the liver. There aren’t any GLP-1 receptors within the liver. So GLP-1 works extra by way of the metabolic pathway by way of urge for food suppression and weight reduction, whereas glucagon works immediately within the liver. So the concept is to mix 2 mechanisms in a single molecule to have each direct impact within the liver and mix that with the metabolic advantages of weight reduction.
It is also rationally designed to have a singular PK profile. We’ve a proprietary area on pemvidutide name EuPort area. And what that does, that slows down the entry of the drug into the bloodstream. So we’ve got longer
[ad_2]
